Journal article icon

Journal article

Bromodomains: are readers right for epigenetic therapy?

Abstract:
There is intense interest in the development of small molecule inhibitors of the acetyl-lysine-reading bromodomain protein module. These inhibitors represent a way of interfering therapeutically in epigenetic processes, and there are currently two bromodomain inhibitors in clinical trials. The success of these compounds rests on safety aspects of epigenetic target modulation being addressed.
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1021/ml300221t

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MPLS, Chemistry, Organic Chemistry
Journal:
ACS medicinal chemistry letters
Volume:
3
Issue:
9
Pages:
691-694
Publication date:
2012-09-05
DOI:
EISSN:
1948-5875
ISSN:
1948-5875
URN:
uuid:26adf6d5-9a1b-4f50-b4b7-5c7ba70630d7
Source identifiers:
352697
Local pid:
pubs:352697
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP